Cyclacel's founding scientist, Professor Sir David Lane, a globally recognized authority in cell cycle biology, discovered p53, a key tumor suppressor gene that malfunctions in about two-thirds of human cancers. Cyclacel is using cell cycle control, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. Under Professor Lane's guidance, our drug discovery and development programs are focused on CDK2/9 isoforms, which operate as key components of the p53 pathway. These efforts resulted in bringing several molecules into clinical development: CYC065, a second-generation CDK inhibitor and CYC140, a highly selective inhibitor of a mitotic pathway enzyme polo-like kinase 1, and CYC682 (Sapacitabine). Source
No articles found.
Based in South San Francisco, we are a clinical-stage biotechnology company commit...
Based in South San Francisco, we are a clinical...
UNITY Biotechnology is developing therapeutics to extend human healthspan by slowi...
UNITY Biotechnology is developing therapeutics ...
We are a biopharmaceutical company focused on discovering, acquiring, developing a...
We are a biopharmaceutical company focused on d...
Sorrentoâs lead programs with short-term milestones consist of two clinical stag...
Sorrentoâs lead programs with short-term mile...
OncoSec Medical Incorporated is a clinical-stage biotechnology company focused on ...
OncoSec Medical Incorporated is a clinical-stag...
We are an innovative clinical-stage biopharmaceutical company primarily focused on...
We are an innovative clinical-stage biopharmace...
Tocagen is a clinical-stage, cancer-selective gene therapy company developing firs...
Tocagen is a clinical-stage, cancer-selective g...
Join the National Investor Network and get the latest information with your interests in mind.